ATE237638T1 - Rekombinante antikörper zur humanen therapie - Google Patents

Rekombinante antikörper zur humanen therapie

Info

Publication number
ATE237638T1
ATE237638T1 AT92917108T AT92917108T ATE237638T1 AT E237638 T1 ATE237638 T1 AT E237638T1 AT 92917108 T AT92917108 T AT 92917108T AT 92917108 T AT92917108 T AT 92917108T AT E237638 T1 ATE237638 T1 AT E237638T1
Authority
AT
Austria
Prior art keywords
recombinant antibodies
human therapy
therapy
human
recombinant
Prior art date
Application number
AT92917108T
Other languages
English (en)
Inventor
Roland A Newman
Nabil Hanna
Ronald W Raab
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE237638(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Application granted granted Critical
Publication of ATE237638T1 publication Critical patent/ATE237638T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92917108T 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie ATE237638T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73506491A 1991-07-25 1991-07-25
US85628192A 1992-03-23 1992-03-23
PCT/US1992/006194 WO1993002108A1 (en) 1991-07-25 1992-07-24 Recombinant antibodies for human therapy

Publications (1)

Publication Number Publication Date
ATE237638T1 true ATE237638T1 (de) 2003-05-15

Family

ID=27112830

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02012106T ATE327331T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie
AT92917108T ATE237638T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02012106T ATE327331T1 (de) 1991-07-25 1992-07-24 Rekombinante antikörper zur humanen therapie

Country Status (24)

Country Link
EP (3) EP0605442B1 (de)
JP (1) JP3048640B2 (de)
KR (1) KR0137806B1 (de)
AP (1) AP307A (de)
AT (2) ATE327331T1 (de)
AU (1) AU673499B2 (de)
BG (1) BG62656B1 (de)
BR (1) BR9206313A (de)
CA (1) CA2114015C (de)
CZ (1) CZ289472B6 (de)
DE (2) DE69233011T2 (de)
DK (2) DK1266965T3 (de)
ES (2) ES2265005T3 (de)
FI (1) FI117703B (de)
HU (2) HUT70272A (de)
IL (1) IL102640A0 (de)
MY (1) MY121185A (de)
NO (1) NO318097B1 (de)
NZ (1) NZ243706A (de)
OA (1) OA09879A (de)
PT (1) PT100735B (de)
RO (1) RO116404B1 (de)
SK (2) SK285960B6 (de)
WO (1) WO1993002108A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
ES2199216T3 (es) * 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
ES2151054T3 (es) * 1994-04-26 2000-12-16 Kanebo Ltd Farmaco para el tratamiento de la artritis reumatoide.
WO1996012741A1 (en) * 1994-10-25 1996-05-02 Glaxo Group Limited Binding agents to cd23
JP2001506122A (ja) * 1994-12-07 2001-05-15 エフ．ホフマン−ラ ロシュ アーゲー 免疫抑制作用を有するモノクローナル抗体断片
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1946775A3 (de) 1998-08-11 2008-08-06 Biogen Idec Inc. Kombinationstherapien für B-Zellen-Lymphome mit Verabreichung eines Anti-CD20-Antikörpers
KR101092132B1 (ko) 1998-11-09 2011-12-12 바이오겐 아이덱 인크. 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법
US7820161B1 (en) 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
AU2001271614B2 (en) * 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
EP1299556A2 (de) * 2000-07-03 2003-04-09 Gala Design, Inc. Wirtzellen, die mehrere intergrationsvektoren enthalten
AU7025201A (en) 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
EP2330130B1 (de) 2002-10-17 2014-08-27 Genmab A/S Humane monoklonale Antikörper gegen CD20
EP1692174A2 (de) * 2003-11-07 2006-08-23 Amgen Inc. Affen-immunoglobulinsequenzen
US7883703B2 (en) 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
KR100942849B1 (ko) 2004-03-30 2010-02-17 글락소 그룹 리미티드 면역글로불린
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
RU2008110058A (ru) * 2005-08-15 2009-09-27 Арана Терапьютикс Лимитед (Au) Химерные антитела с областями приматов нового света
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
EA017417B1 (ru) 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
WO2008017126A1 (en) 2006-08-11 2008-02-14 Csl Limited Treatment of pulmonary disease conditions
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
PL2829551T3 (pl) 2006-10-19 2018-04-30 Csl Limited Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
DK2068922T3 (da) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
DE202012013147U1 (de) * 2011-10-31 2015-01-22 Jan-Niklas Keltsch Einhändig bedienbare Verpackung
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
AU2018206552A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
MX2019008989A (es) 2017-01-30 2019-10-09 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
AU2017398101A1 (en) 2017-02-07 2019-08-01 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
EP3861021A4 (de) 2018-10-05 2022-06-22 Research Institute at Nationwide Children's Hospital Zusammensetzungen und verfahren zur enzymatischen zerstörung bakterieller biofilme
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
KR20220032066A (ko) 2019-07-08 2022-03-15 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막을 파괴하기 위한 항체 조성물
EP4161574A1 (de) 2020-06-04 2023-04-12 BioInvent International AB Verbesserung der verträglichkeit von antikörpern im zusammenhang mit intravenöser verabreichung
IL305469A (en) 2021-03-09 2023-10-01 Bioinvent Int Ab New combinations of antibodies and their uses
WO2023161448A1 (en) 2022-02-24 2023-08-31 Abnomx Bv Human-like target-binding proteins
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2199216T3 (es) * 1991-07-15 2004-02-16 The Wellcome Foundation Limited Produccion de anticuerpos.

Also Published As

Publication number Publication date
FI117703B (fi) 2007-01-31
FI940336A (fi) 1994-03-10
PT100735B (pt) 1999-07-30
EP1715045A2 (de) 2006-10-25
NO940219L (no) 1994-03-25
BR9206313A (pt) 1995-04-11
BG98411A (bg) 1995-02-28
ATE327331T1 (de) 2006-06-15
SK8894A3 (en) 1994-09-07
SK285960B6 (sk) 2007-12-06
WO1993002108A1 (en) 1993-02-04
AU2425592A (en) 1993-02-23
RO116404B1 (ro) 2001-01-30
EP1266965B1 (de) 2006-05-24
DE69233628T2 (de) 2007-04-26
AP307A (en) 1994-01-31
KR0137806B1 (ko) 1998-04-30
CZ289472B6 (cs) 2002-01-16
ES2196002T3 (es) 2003-12-16
EP1266965A2 (de) 2002-12-18
DK0605442T3 (da) 2003-08-04
HU211881A9 (en) 1995-12-28
OA09879A (en) 1994-09-15
SK285046B6 (sk) 2006-05-04
HU9400201D0 (en) 1994-05-30
CA2114015A1 (en) 1993-02-04
MY121185A (en) 2006-01-28
IL102640A0 (en) 1993-01-14
DE69233628D1 (de) 2006-06-29
NO940219D0 (no) 1994-01-21
JPH06509708A (ja) 1994-11-02
EP0605442B1 (de) 2003-04-16
DK1266965T3 (da) 2006-09-25
HUT70272A (en) 1995-09-28
EP1715045A3 (de) 2006-12-13
BG62656B1 (bg) 2000-04-28
NZ243706A (en) 1994-08-26
NO318097B1 (no) 2005-01-31
EP0605442A1 (de) 1994-07-13
EP1266965A3 (de) 2003-01-02
FI940336A0 (fi) 1994-01-24
DE69233011T2 (de) 2003-11-06
JP3048640B2 (ja) 2000-06-05
PT100735A (pt) 1993-10-29
CA2114015C (en) 2002-12-10
AP9200413A0 (en) 1992-07-31
CZ14994A3 (en) 1994-07-13
EP0605442A4 (de) 1995-07-12
DE69233011D1 (de) 2003-05-22
ES2265005T3 (es) 2007-02-01
AU673499B2 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
DE69233011D1 (de) Rekombinante antikörper zur humanen therapie
NO980915L (no) Rekombinante anti-CD4-antistoff egnet for human terapi
NO924395D0 (no) Rekombinante menneske-faktor viii derivater
FI935175A (fi) Tyrosinkinas- HER4-humanreceptor
ITTO920014V0 (it) Dispositivo di copertura per arto artificiale
DE69230061D1 (de) Künstliches immunoglobulin-bindendes protein
DK64592D0 (da) Peptider til terapeutisk behandling
FI941749A (fi) Rekombinantti-Borrelia -proteiinien valmistus
EP0540575A4 (en) Human meg-csf protein and methods
ZA925615B (en) Recombinant antibodies for human therapy
FI920701A (fi) Anordning foer terapeutisk tryckbehandling
DK149591A (da) Proteinpraeparat
DE69434900D1 (de) Menschliche chemokin-polypeptide
EP0463571A3 (en) Recombinant human osteocalcin
DK147891D0 (da) Proteinpraeparat
IE883256L (en) Human immunoglobulins by recombinant dna techniques
MD279B1 (ro) Metoda de terapie tisulara
ITPD910230A0 (it) Nuovi anticorpi monoclonali specifici per il fattore neurofonico ciliare (cntf) umano ricombinante
LV10690A (lv) Asins olbaltumvielu sadalisanas panemiens
SE9502576D0 (sv) Therapeutic preparations for inhalation II
ITMI920634A0 (it) Dispositivo perfezionato per respirazione artificiale
GB9120944D0 (en) Modified human serum albumin
FI924616A0 (fi) Potilassänky
LV10393A (lv) Savietojams cilveka olbaltumvielas preparats
IT9001216A0 (it) Sedia terapeutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0605442

Country of ref document: EP

REN Ceased due to non-payment of the annual fee